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ABSTRACT 29 
Background.  Oral squamous cell carcinoma (OSCC) is a major healthcare problem worldwide.  30 
Efforts in our laboratory and others focusing on the molecular characterization of OSCC tumors 31 
with the use of DNA microarrays have yielded heterogeneous results.  To validate the DNA 32 
microarray results on a subset of genes from these studies that could potentially serve as 33 
biomarkers of OSCC, we elected to examine their expression by an alternate quantitative method 34 
and by assessing their protein levels.   35 
Design.  Based on DNA microarray data from our lab and data reported in the literature, we 36 
identified six potential biomarkers of OSCC to investigate further.  We employed quantitative, 37 
real-time polymerase chain reaction (qRT-PCR) to examine expression changes of CDH11, 38 
MMP3, SPARC, POSTN, TNC, TGM3 in OSCC and normal control tissues.  We further 39 
examined validated markers on the protein level by immunohistochemistry (IHC) analysis of 40 
OSCC tissue microarray (TMA) sections.    41 
Results.  qRT-PCR analysis revealed up-regulation of CDH11, SPARC, POSTN, and TNC gene 42 
expression, and decreased TGM3 expression in OSCC compared to normal controls.  MMP3 was 43 
not found to be differentially expressed.  In TMA IHC analyses, SPARC, periostin, and tenascin 44 
C exhibited increased protein expression in cancer compared to normal tissues, and their 45 
expression was primarily localized within tumor-associated stroma rather than tumor epithelium.  46 
Conversely, transglutaminase-3 protein expression was found only within keratinocytes in 47 
normal controls, and was significantly down-regulated in cancer cells.   48 
Conclusions.  Of six potential gene markers of OSCC, initially identified by DNA microarray 49 
analyses, differential expression of CDH11, SPARC, POSTN, TNC, and TGM3 were validated by 50 
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qRT-PCR.  Differential expression and localization of proteins encoded by SPARC, POSTN, 51 
TNC, and TGM3 were clearly shown by TMA IHC. 52 
 53 
Introduction 54 
 Head and neck squamous cell carcinoma (HNSCC) is the 5th most common cancer 55 
worldwide.1  The American Cancer Society estimates that approximately 30,990 Americans were 56 
diagnosed with and 7,430 died of cancer of the oral cavity and pharynx in 2006.2  Despite 57 
considerable advances in the treatment of HNSCC over the past two decades, overall disease 58 
outcomes have only modestly improved.2  Local tumor recurrence affects approximately 60% of 59 
patients and metastases develops in 15-25%.3  Less than 30% of HNSCC patients experience 60 
three or more years of disease-free survival, and many suffer from impaired speech, swallowing, 61 
and/or breathing due to the sensitive location of HNSCC tumors within the upper aerodigestive 62 
tract.4  Of the various subgroups of HNSCC, oral squamous cell carcinoma (OSCC) is the most 63 
common, representing about 75% of all HNSCC cases.2  High throughput investigation into the 64 
molecular characteristics of HNSCC has mainly utilized DNA microarray technology to search 65 
for gene expression profiles associated with disease and disease outcomes.  The literature on 66 
DNA microarray profiling of HNSCC shows heterogeneity in the specific genes that were found 67 
to be up- or down-regulated in HNSCC.  After comparing results from multiple studies, we 68 
reported a list of genes commonly found to have dysregulated expression in HNSCC tumors.5  69 
Only a handful of these gene expression alterations have been validated by alternate 70 
experimental methodologies such as qRT-PCR, Western blot, Northern blot, and IHC.  Even 71 
fewer have been examined for their correlation with disease severity and metastasis status.   72 
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Based on various selection criteria (see Materials & Methods), we selected six genes to 73 
analyze further: CDH11, MMP3, SPARC, POSTN, TNC, and TGM3.  CDH11 encodes an 74 
integral membrane protein, cadherin-11, which mediates cell-cell adhesion and thought to be 75 
involved in bone cell differentiation and bone formation.6  MMP3 encodes a secreted protease, 76 
matrix metalloproteinase-3, whose action is to degrade the major components of the extracellular 77 
matrix (ECM), and is thought to be associated with cervical lymph node metastases in HNSCC.7  78 
SPARC (secreted protein, acidic, rich in cysteine), encodes an ECM-associated protein, a.k.a. 79 
osteonectin, that inhibits cell-cycle progression, causes changes in cell shape, and influences 80 
ECM synthesis.8  SPARC has also been found to be an independent prognostic marker for short 81 
disease-free interval and poor overall survival in HNSCC patients.9  POSTN encodes the protein, 82 
periostin, which is a ligand for various integrins and as such, supports adhesion and migration of 83 
epithelial cells.10  Periostin is thought to promote invasion and angiogenesis in OSCC.11,12  TNC 84 
encodes an ECM protein, tenascin-C, that regulates cell adhesion, migration, and growth.13  85 
TGM3 encodes transglutaminase-3, which crosslinks intracellular structural proteins and is 86 
important in cell envelope formation of the epidermis.14  Transglutaminase-3 is expressed 87 
normally in terminally differentiated epithelial cells.15  It has been shown to be down-regulated 88 
in esophageal squamous cell carcinoma16-18 and in the progression of oral leukoplakia to 89 
OSCC.19  CDH11, MMP3, SPARC, POSTN, and TNC have all been shown in gene microarray 90 
experiments to be significantly upregulated in cancer tissues compared to normal controls, 91 
whereas TGM3 is significantly down-regulated.5 92 
 93 
 94 
 95 
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Materials & Methods 96 
Biomarker Selection.  The criteria for choosing potential OSCC markers for the current study 97 
were:  1) genes from our own DNA microarray data that show the highest Z-scores and greatest 98 
expression fold changes between cancer and normal;20 2) these genes have been shown to have 99 
significantly altered expression in OSCC when compared with non-cancer tissues in at least four 100 
other laboratories, and 3) the genes had available antibodies against their encoded protein 101 
products for use in IHC analyses.     102 
 103 
qRT-PCR.  Differential gene expression of CDH11, MMP3, SPARC, POSTN, TNC, and TGM3 104 
between normal and cancer specimens was quantified by using SYBR® Green I technology and 105 
melting-point dissociation curve analyses per manufacturer protocol (Applied Biosystems, Foster 106 
City, CA).  Total RNA extracted from six normal tissue samples and six tumor tissue samples 107 
(Table 1) were used as templates in RT-PCR reactions to generate cDNA.  Each sample was 108 
divided into five wells for the qRT-PCR reactions: three for the gene of interest and two for the 109 
endogenous control, glyceraldehyde 3-phosphate dehydrogenase (GAPDH).  qRT-PCR analyses 110 
were performed on an ABI 5700 Sequence Detector using 10 ng of cDNA and gene specific 111 
primers in 1 × SYBR® Green I PCR Master Mix in a 50-µL reaction.  Cycling parameters were 112 
50 °C for 2 minutes, 95 °C for 10 minutes, and 40 cycles at 95 °C for 15 seconds and at 60 °C 113 
for 1 minute.  Primer sequences were designed using PE/ABI Primer Express® software, checked 114 
for specificity against the National Center for Biotechnology Information nucleotide data base, 115 
and were as follows: CDH11 forward, 5-GCT CAA CCA GCA GAG ACA TTC C-3; CDH11 116 
reverse, 5-AGA ATG CAG CTG TCA CCC CTT-3; MMP3 forward, 5-GGC AAG ACA GCA 117 
AGG CAT AGA-3; MMP3 reverse, 5-TGG ATA GGC TGA GCA AAC TGC-3; SPARC 118 
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forward, 5-CGG CTT TGT GGA CAT CCC TA-3; SPARC reverse, 5-GGA AGG ACT CAT 119 
GAC CTG CAT C-3;  POSTN forward, 5-ACA ACG CAG CGC TAT TCT GAC-3; POSTN 120 
reverse, 5-ATC CAA GTT GTC CCA AGC CTC-3; TNC forward, 5-AGA AAG TCA TCC 121 
GGC ACA AGC-3; TNC reverse, 5-ACT CCA GAT CCA CCG AAC ACT G-3; TGM3 forward, 122 
5-GAC AAG CGC ATC ACA CAG ACA-3; TGM3 reverse, 5-TCT TTC GTT AGA GCC AAG 123 
GCC-3.  Melting-curve analyses were run immediately after cycling to verify specificity of the 124 
reactions.  Quantification of the transcripts was determined by choosing a fluorescence threshold 125 
at which the amplification of the target gene was exponential in both tumor samples and normal 126 
samples.  The PCR cycle number at which the amplification curve intercepted the threshold is 127 
termed the threshold cycle (CT).  The threshold cycle is inversely proportional to the copy 128 
number of the target template.  Relative fold changes were calculated by 2- ΔΔCT, where ΔΔCT = 129 
[average CT, gene j - average CT, GAPDH] tumor tissue - [average CT, gene j - average CT, 130 
GAPDH] normal tissue. 131 
 132 
TMA Construction.  TMA blocks (one master and one copy) were constructed with the use of an 133 
automated tissue arrayer per manufacturer protocol (Beecher Instruments, Sun Prairie, WI).  134 
Formalin-fixed, paraffin-embedded tissue specimens were obtained from the University of 135 
Washington, Department of Pathology under Institutional Review Board approval by the Human 136 
Subjects Division at the University of Washington and the Fred Hutchinson Cancer Research 137 
Center.  Our TMA is comprised of 63 tissue specimens from 31 patients (Table 2).  Patients 138 
ranged from 28 to 88 years (60±15) in age and three quarters were male (74.2%).  Tissues came 139 
from the oral cavity, oropharynx, and lymph node metastases.  Twenty-four of the tissue 140 
specimens were from primary OSCC tumors, 16 were from normal tissue taken from cancer 141 
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patients, 17 were from cervical lymph node metastases, three were premalignant lesions, and 142 
three were from patients without cancer (normal patients).  Of the 24 tumors, 4 were stage I/II 143 
and 20 were stage III/IV, 12 were T1/T2 and 12 were T3/T4, and 18 had associated cervical 144 
lymph node metastases while 6 were non-metastatic.  Cores were arrayed in quadruplicate, with 145 
a diameter of 0.6 mm.  TMA blocks were stored in a nitrogen chamber for antigen preservation.  146 
Sections were cut at 5 µM for IHC analyses. 147 
 148 
Immunohistochemistry.  Genes that satisfied the following criteria were studied further by IHC 149 
analysis of OSCC TMA sections:  1) gene expression in cancer tissues had to be significantly 150 
different than in normal tissues by each of the two different methods, qRT-PCR and GeneChip® 151 
analysis, and 2) the relative gene expression determined by these two different methods had to be 152 
significantly correlated with one another.   153 
 SPARC IHC was performed using mouse monoclonal anti-SPARC antibody (US 154 
Biological, Swampscott, MA) at a dilution of 1:2000, following antigen retrieval consisting of 20 155 
minutes of non-pressurized steam incubation in 10 mM citrate buffer, pH 6.0.  Periostin IHC was 156 
performed using rabbit polyclonal anti-periostin antibody (BioVendor, Candler, NC; 157 
http://biovendor.com/pdf/RD181045050.pdf) at a dilution of 1:900.  Tenascin-C IHC was 158 
performed using mouse monoclonal anti-tenascin-C antibody (BioVendor, Candler, NC; 159 
http://biovendor.com/pdf/RE11370C100.pdf) at a dilution of 1:50 following antigen retrieval 160 
consisting of two, five-minute microwave incubations in 10 mM citrate buffer, pH 6.0.  161 
Transglutaminase-3 IHC was performed using mouse monoclonal antibody (a generous gift from 162 
Dr. Kiyotaka Hitomi, Nagoya University, Nagoya, Japan) raised against purified, recombinant 163 
human TGase-3,15 at a dilution of 1:1000.  TMA sections incubated with antibody diluent alone, 164 
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phosphate buffered saline (PBS) containing 1% bovine serum albumin, served as negative 165 
controls to confirm specificity of immunostaining for all markers.   166 
 Slides were deparaffinized by three changes of xylene, seven minutes each, and 167 
rehydrated by three changes of 100% ethanol x two minutes, two changes of 95% ethanol x two 168 
minutes, and one change of 70% ethanol x one minute.  Endogenous peroxidase activity was 169 
blocked by incubation in 0.3% H2O2 at room temperature for 10 minutes.  Non-specific binding 170 
sites were subsequently blocked with 2% normal goat serum (Vector Laboratories, Burlingame, 171 
CA) in PBS, pH 7.4, at room temperature for 15 minutes.  Slides were then washed and 172 
incubated with primary antibody.  Washes consisted of a five-minute soak in PBS, pH 7.4, 173 
followed by 10 dips in PBS with 1% BSA and 0.01% Triton-X-100 (Sigma, St. Louis, MO), pH 174 
7.4, and a second five-minute wash in PBS, pH 7.4.  TMA slides were then incubated with 175 
primary antibody at the above listed dilutions in PBS with 1% BSA, pH 7.4, at room temperature 176 
for one hour in a humidity chamber (Shandon Lipshaw, Inc, Pittsburgh, PA).  Sections were then 177 
washed again as before, incubated with either biotinylated goat anti-mouse or biotinylated goat 178 
anti-rabbit secondary antibody (Vector Laboratories, Burlingame, CA), washed again, and 179 
subsequently incubated with ABC Elite reagent (Vector Laboratories, Burlingame, CA) per 180 
manufacturer protocol.  Slides were then stained by incubation with 0.08% diaminobenzidine, 181 
0.01% FeCl3 in 0.05 M Tris buffer, pH 8.0 (Sigma, St. Louis, MO) at 37°C for seven minutes.  182 
Sections were counterstained with Mayers Hematoxylin (Dako Cytomation, Carpinteria, CA), 183 
dehydrated, mounted with Cytoseal 60 (Richard-Allan Scientific, Kalamazoo, MI) and covered 184 
with a coverslip. 185 
 186 
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Scoring of IHC results.    Images of the IHC-stained TMA sections were digitized using the 187 
BLISS Tracer imaging system and visualized with WebSlide Server software (Bacus 188 
Laboratories, Lombard, IL).  Marker immunoreactivity was scored using a validated, modified 189 
H-score system21 by a board-certified pathologist (C.D.J.), blinded to all characteristics of the 190 
cases and controls.  IHC scores were determined by taking the product of the estimated staining 191 
intensity (0, 1+, 2+, 3+) and area of tissue (tumor or normal; epithelial or stromal) stained (0% = 192 
0, <25% = 1, 25-75% = 2, >75% = 3), giving a range of possible scores between 0 and 9.  IHC 193 
scores for replicate cores were averaged to determine a composite score for each case.     194 
 195 
Statistical Analysis.  qRT-PCR results were analyzed by an unpaired Student’s t-test to compare 196 
gene expression between cancer and normal specimens.  Relative gene expression values 197 
determined by qRT-PCR analyses were then compared with those previously determined by gene 198 
microarray analyses20 by linear regression analysis.  Pairwise comparisons of IHC scores were 199 
made between primary tumor tissue and normal mucosa, tumor tissue and lymph nodes, tumor 200 
tissue and CIS, and CIS tissue and normal mucosa, using unpaired Student’s t-tests.   Because of 201 
multiple comparisons, we felt that a threshold of P<.05 was too low, and considered comparisons 202 
to be statistically significant only if P<.01.  All statistical analyses were performed using Stata 203 
9.0 software (StataCorp, College Station, TX).     204 
 205 
Results 206 
CDH11, SPARC, POSTN, TNC, and TGM3 exhibited significant differences in 207 
expression between cancer and normal specimens by qRT-PCR (Table 3).  There was a trend 208 
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towards up-regulation of MMP3 expression in cancer compared to normal specimens, but this 209 
did not reach statistical significance. 210 
 Results of the linear regression analyses show good correlation between relative gene 211 
expression as determined by qRT-PCR and that previously determined by DNA microarray20 on 212 
the same specimens for MMP3, SPARC, POSTN, TNC, and TGM3 (Table 3).  Correlation 213 
between qRT-PCR and gene microarray expression data for CDH11 did not reach statistical 214 
significance (r = 0.45, p ≤ 0.14).   215 
Representative TMA cores stained for SPARC, periostin, tenascin-C, and 216 
transglutaminase-3 are shown for both normal mucosa and primary OSCC tumors (Figure 1).  217 
Staining with antibodies to SPARC was predominantly localized to vessels, fibroblasts, and 218 
subsets of carcinoma cells.  Virtually no epithelial cell staining was observed in normal mucosa 219 
(Figure 1A).  SPARC IHC staining in epithelium, fibroblasts, and vessels was significantly 220 
higher in tumor specimens compared to normal controls (Figure 1B, Table 4).  There were no 221 
significant differences with regard to epithelial SPARC expression among tumors of different 222 
TNM stage.   223 
Staining with antibodies to periostin was predominantly associated with fibroblasts and 224 
the ECM.  Expression was significantly higher in cancer versus normal controls (Figure 1C-D, 225 
Table 4).  Epithelial cancer cells in over half (14/24, 58.3%) of the primary tumors and 226 
approximately one fourth (4/17, 23.5%) of the cervical metastatic tumors exhibited faint staining, 227 
whereas the remaining tumors were completely negative for epithelial cell staining.  Of the 228 
tumors that were positive for epithelial staining, 13/14 (92.8%) were stage III/IV tumors 229 
representing 65% of the 20 stage III/IV tumors examined, whereas only one (7.2%) was an early 230 
stage  tumor (Case 16, a recurrent T2N0M0), representing one of the four stage I/II tumors 231 
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examined.  In addition, all 8 (100%) of the T4 tumors on our TMA were positive for epithelial 232 
periostin staining.  Non-neoplastic epithelium was virtually negative for staining.  Staining of 233 
carcinoma cells was, on average, higher in primary tumors compared to cervical lymph node 234 
metastases (Table 4).  Average ECM staining of periostin also was greater in primary tumors 235 
compared to that within the metastatic lymph nodes (Table 4).   236 
Staining with antibodies to tenascin-C was predominantly localized to the ECM (Figure 237 
1E-F).  In normal mucosa, only the region of ECM immediately adjacent to the basal epithelium 238 
showed moderate staining.  Tenascin-C staining in the ECM was significantly higher in OSCC 239 
tumors compared to normal mucosa (Table 4).  Staining was occasionally associated with 240 
carcinoma cells, particularly in tumor regions directly adjacent to desmoplastic stroma. 241 
Staining with antibodies to transglutaminase-3 localized only within epithelial cells; no 242 
stromal expression was observed (Figure 1G-H).  Within non-neoplastic epithelium, the 243 
suprabasal layers stained intensely, while the basal layer of epithelial cells was negative for 244 
staining.  Staining in invasive carcinomas was patchy, and when present, was typically 245 
associated with areas of increased differentiation and keratinization.  Many carcinomas were 246 
completely negative for staining.  There were statistically significant differences in 247 
transglutaminase-3 immunoreactivity between different specimen groups, such that the highest 248 
expression was seen in non-neoplastic epithelium, with significantly lower expression in CIS 249 
specimens, and stepwise significantly lower expression in primary tumors (Table 4).   250 
 251 
Discussion 252 
 We selected six potential biomarkers of OSCC for the current validation study by 253 
examining DNA microarray data both from our laboratory, as well as that published in the 254 
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literature.5  SPARC, POSTN, TNC, and TGM3 microarray expression differences were validated 255 
by both qRT-PCR and IHC of TMA sections.    The qRT-PCR results for MMP3 and CDH11 did 256 
not reach statistical significance.  In contrast with another IHC study reporting high levels of 257 
periostin expression within oral carcinoma epithelium,12 we noted periostin staining to be 258 
localized primarily to the stroma and did not see robust staining within tumor cells themselves 259 
(Figure 1D).  The reason for this disparity in IHC staining is unclear.  Non-overlapping antibody 260 
epitopes may partially explain the disparity of periostin IHC staining patterns.  The antibody we 261 
used for periostin IHC was raised in rabbits against recombinant human periostin containing 648 262 
amino acid residues (corresponding to amino acids 22-669 of full-length periostin) with an N-263 
terminal HisTag fusion (http://biovendor.com/pdf/RD181045050.pdf), whereas periostin IHC 264 
experiments by Siriwarden et al. utilized a polyclonal antibody generated by immunizing rabbits 265 
with a specific peptide (EGEPEFRLIKEGETC) corresponding to amino acids 679-692 of full-266 
length periostin.12   267 
Despite the strong stromal predominance of periostin expression we observed, the 268 
percentage of OSCC tumors positive for epithelial periostin in our study (58%) was comparable 269 
to that reported by Siriwarenda et al.12 (69%).  A majority (65%) of the stage III/IV OSCC 270 
tumors, including 100% of T4 tumors we examined, were positive for epithelial periostin 271 
immunostaining, compared to only 25% of the stage I/II tumors.  These findings suggest that 272 
epithelial expression of periostin may be associated with a more aggressive tumor phenotype in 273 
OSCC.  This is supported by other studies, which show that subsets of HNSCC cells expressing 274 
periostin, or cells engineered to overexpress periostin, exhibit enhanced tumor growth and 275 
invasiveness, and tumors that express periostin have a more invasive phenotype.11,12   276 
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We found the proportion of metastatic lymph node tumors positive for epithelial periostin 277 
expression (23.5%) was less than half that of primary tumors (58.3%).  However, each of the 278 
positively stained lymph node tumors was associated with a primary tumor that also had 279 
epithelial periostin expression, suggesting that presence of periostin in the epithelium of primary 280 
tumors may be necessary, but not sufficient, for its presence in metastatic tumors.   281 
In oral and laryngeal squamous cell carcinoma, increased levels of tenascin-C 282 
immunostaining have been found to correlate with malignancy and invasion22-25  Abundant 283 
expression of tenascin-C in our OSCC TMA sections was localized primarily to the stroma, 284 
although some minor staining of tumor cells was also observed, particularly at tumor edges 285 
adjacent to desmoplastic stroma.  This observation is consistent with reports in the literature 286 
showing tenascin-C localization along the invasive fronts of carcinomas of the lung, liver, 287 
bladder, and skin.26,27   288 
Roepman, et al.28 and Schmalbach, et al.29 identified TGM3 to be significantly down-289 
regulated in metastatic HNSCC compared to both non-metastatic tumors and normal epithelium.  290 
O’Donnell et al.30 similarly found significant down-regulation of TGM3 gene expression in 291 
metastatic primary OSCC tumors compared to non-metastatic primaries.  Our cross-sectional 292 
IHC data show that the levels of transglutaminase-3 protein expression were seen to decrease in 293 
a stepwise fashion from normal to premalignant to malignant specimens.  This suggests that the 294 
loss of transglutaminase-3 activity might be associated with the progression of squamous cell 295 
carcinoma.  296 
  All of the up-regulated gene markers we identified by reviewing gene microarray 297 
reports, validated by qRT-PCR, and subsequently studied with IHC revealed protein expression 298 
to be localized primarily within the stroma, and modestly or not at all within tumor cells.  This 299 
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finding illustrates an important point regarding the interpretation of gene microarray data based 300 
on the methodology used for specimen processing.  The methods employed by different 301 
laboratories for tumor specimen processing vary significantly.5  While some investigators 302 
isolated relatively homogeneous populations of tumor cells for microarray analysis via laser 303 
capture microdissection (LCM), others established arbitrary thresholds for minimum tumor cell 304 
content in surgical specimens, as assessed by histologic evaluation of adjacent tissue, prior to 305 
RNA extraction and microarray analysis.  The latter method clearly results in varying amounts of 306 
stromal cells contributing to the final pool of extracted RNA, and thus the variability of the 307 
resultant microarray data.  Notably, even LCM does not ensure isolation of a purely 308 
homogeneous population of tumor cells, as varying degrees of leukocytosis and 309 
neovascularization within tumors exist and correlate with survival, tumor stage, metastases, and 310 
presence of extracapsular spread in HNSCC.31-33   311 
Up-regulation of SPARC, POSTN, or TNC was not reported by any of the DNA 312 
microarray studies that examined expression of HNSCC cell lines34-36 or by others that employed 313 
LCM to isolate tumor cells from stroma.37-40  Presumably this is due to the relative absence of 314 
stromal cells within the analyzed specimens in these studies, although absence of one or more of 315 
these markers on the microarrays used by these studies may also contribute.  These findings, 316 
together with the IHC data we report here, suggest that up-regulation of SPARC, POSTN, and 317 
TNC is due to 1) up-regulation within stromal cell populations vs carcinoma cells and/or 2) 318 
stroma-induced transcriptional upregulation of these markers in cancer cells.  In any case, these 319 
observations underscore the importance in examining both tumor and stroma in the pathogenesis 320 
of OSCC.   321 
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  The “seed and soil” hypothesis of tumor-stromal interaction was originally proposed by 322 
Paget in 1889, but only recently have researchers examined how tumor microenvironments 323 
influence the growth and spread of cancers.  Carcinoma-associated fibroblasts (CAFs), ECM 324 
macromolecules, neovascularization, and inflammatory and immune cell infiltration within the 325 
stroma adjacent to tumors can have profound effects on tumor progression in breast, prostate, 326 
and skin carcinomas.41  The situation in OSCC is less well understood, but studies of CAFs, 327 
ECM turnover and tumor cell motility have begun to delineate the role of desmoplastic stroma in 328 
OSCC carcinogenesis.42-44  Recently, Weber et al.45 performed genome-wide analysis of loss of 329 
heterozygosity (LOH) and allelic imbalance (AI) on LCM-isolated specimens of tumor stroma 330 
and tumor epithelium from over 120 OSCC patients with a history of smoking.  They discovered 331 
over 40 hot spots of LOH/AI within the stroma, nearly twice as many as they found in the 332 
epithelium, and subsequently identified three stroma-specific loci that were significantly 333 
associated with tumor size and cervical lymph node metastasis.45  These findings again highlight 334 
the importance of examining both stromal as well as epithelial elements in OSCC, and suggest 335 
that stromal alterations play a crucial part in facilitating OSCC invasion and metastasis.   336 
 337 
Conclusions 338 
Our observations indicate that significant changes in the expression of four genes, 339 
SPARC, POSTN, TNC, and TGM3, initially identified by gene microarray studies, are associated 340 
with similar changes in protein expression based on IHC analyses.  The localization of SPARC, 341 
periostin, tenascin-C predominately within the stroma of OSCC tumors supports the idea that 342 
stromal elements are important in OSCC pathogenesis.   343 
 344 
TMA paper  Choi P, et al. 
 
16
Acknowledgments.  This review was supported by grant R01 CA 095419-01A1 from the 345 
National Institutes of Health, National Cancer Institute, Bethesda, MD; National Research 346 
Service Award T32 DC00018 from the National Institutes of Health, National Institute on 347 
Deafness and Other Communication Disorders, Bethesda, MD; and in part by Fred Hutchinson 348 
Cancer Research Center Funds.   349 
 350 
References 351 
 352 
 1.  Sankaranarayanan,R, Masuyer,E, Swaminathan,R, Ferlay,J, Whelan,S. Head and neck 353 
cancer: a global perspective on epidemiology and prognosis. [Review] [14 refs]. Anticancer 354 
Res. 1998;18:4779-4786. 355 
 2.  Ries, L. A. G., Harkins, D., Krapcho, M., Mariotto, A., Miller, B. A., Feuer, E. J., Clegg, 356 
L., Eisner, M. P., Horner, M. J., Howlader, N., Hankey, B. F., and Edwards, B. K. SEER 357 
Cancer Statistics Review 1975-2003.  2006.  National Cancer Institute.  358 
 3.  Genden,EM, Ferlito,A, Bradley,PJ, Rinaldo,A, Scully,C. Neck disease and distant 359 
metastases. Oral Oncology. 2003;39:207-212. 360 
 4.  Dimery,IW, Hong,WK. Overview of combined modality therapies for head and neck 361 
cancer. [Review] [231 refs]. J.Natl.Cancer Inst. 1993;85:95-111. 362 
 5.  Choi,P, Chen,C. Genetic Expression Profiles and Biologic Pathway Alterations in Head 363 
and Neck Squamous Cell Carcinoma. Cancer. 2005;104:1113-1128. 364 
 6.  Okazaki,M, Takeshita,S, Kawai,S et al. Molecular cloning and characterization of OB-365 
cadherin, a new member of cadherin family expressed in osteoblasts. J.Biol.Chem. 366 
1994;269:12092-12098. 367 
 7.  Wiegand,S, Dunne,AA, Muller,HH et al. Metaanalysis of the significance of matrix 368 
metalloproteinases for lymph node disease in patients with head and neck squamous cell 369 
carcinoma. Cancer. 2005;104:94-100. 370 
 8.  Bradshaw,AD, Graves,DC, Motamed,K, Sage,EH. SPARC-null mice exhibit increased 371 
adiposity without significant differences in overall body weight. Proc.Natl.Acad.Sci.U.S.A. 372 
2003;100:6045-6050. 373 
 9.  Chin,D, Boyle,GM, Williams,RM et al. Novel markers for poor prognosis in head and neck 374 
cancer. Int.J.Cancer. 2005;113:789-797. 375 
TMA paper  Choi P, et al. 
 
17
 10.  Gillan,L, Matei,D, Fishman,DA, Gerbin,CS, Karlan,BY, Chang,DD. Periostin secreted by 376 
epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins 377 
and promotes cell motility. Cancer Res. 2002;62:5358-5364. 378 
 11.  Kudo,Y, Ogawa,I, Kitajima,S et al. Periostin promotes invasion and anchorage-379 
independent growth in the metastatic process of head and neck cancer. Cancer Res. 380 
2006;66:6928-6935. 381 
 12.  Siriwardena,BS, Kudo,Y, Ogawa,I et al. Periostin is frequently overexpressed and 382 
enhances invasion and angiogenesis in oral cancer. Br.J.Cancer. 2006;95:1396-1403. 383 
 13.  Jones,FS, Jones,PL. The tenascin family of ECM glycoproteins: structure, function, and 384 
regulation during embryonic development and tissue remodeling. Dev.Dyn. 2000;218:235-385 
259. 386 
 14.  Kim,IG, Gorman,JJ, Park,SC, Chung,SI, Steinert,PM. The deduced sequence of the novel 387 
protransglutaminase E (TGase3) of human and mouse. J.Biol.Chem. 1993;268:12682-388 
12691. 389 
 15.  Hitomi,K, Presland,RB, Nakayama,T, Fleckman,P, Dale,BA, Maki,M. Analysis of 390 
epidermal-type transglutaminase (transglutaminase 3) in human stratified epithelia and 391 
cultured keratinocytes using monoclonal antibodies. J.Dermatol.Sci. 2003;32:95-103. 392 
 16.  Luo,A, Kong,J, Hu,G et al. Discovery of Ca2+-relevant and differentiation-associated 393 
genes downregulated in esophageal squamous cell carcinoma using cDNA microarray. 394 
Oncogene. 2004;23:1291-1219. 395 
 17.  Liu,W, Yu,ZC, Cao,WF, Ding,F, Liu,ZH. Functional studies of a novel oncogene TGM3 in 396 
human esophageal squamous cell carcinoma. World J of Gastroenterol. 2006;12:3929-397 
3932. 398 
 18.  Chen,BS, Wang,MR, Xu,X et al. Transglutaminase-3, an esophageal cancer-related gene. 399 
Int.J.Cancer. 2000;88:862-865. 400 
 19.  Ohkura,S, Kondoh,N, Hada,A et al. Differential expression of the keratin-4, -13, -14, -17 401 
and transglutaminase 3 genes during the development of oral squamous cell carcinoma 402 
from leukoplakia. Oral Oncol. 2005;41:607-613. 403 
 20.  Mendez,E, Cheng,C, Farwell,DG et al. Transcriptional expression profiles of oral 404 
squamous cell carcinomas. Cancer. 2002;95:1482-1494. 405 
 21.  Budwit-Novotny,DA, McCarty,KS, Cox,EB et al. Immunohistochemical analyses of 406 
estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer 407 
Res. 1986;46:5419-5425. 408 
 22.  Zidar,N, Gale,N, Kambic,V, Fischinger,J. Expression of tenascin and fibronectin in benign 409 
epithelial hyperplastic lesions and squamous carcinoma of the larynx. Anticancer Res. 410 
2001;21:451-454. 411 
TMA paper  Choi P, et al. 
 
18
 23.  Juhasz,A, Bardos,H, Repassy,G, Adany,R. Characteristic distribution patterns of tenascin 412 
in laryngeal and hypopharyngeal cancers. Laryngoscope. 2000;110:84-92. 413 
 24.  Hindermann,W, Berndt,A, Borsi,L et al. Synthesis and protein distribution of the unspliced 414 
large tenascin-C isoform in oral squamous cell carcinoma. J.Pathol. 1999;189:475-480. 415 
 25.  Regezi,JA, Ramos,DM, Pytela,R, Dekker,NP, Jordan,RC. Tenascin and beta 6 integrin are 416 
overexpressed in floor of mouth in situ carcinomas and invasive squamous cell carcinomas. 417 
Oral Oncol.  2002;38:332-336. 418 
 26.  Dang,C, Gottschling,M, Roewert,J, Forschner,T, Stockfleth,E, Nindl,I. Tenascin-C patterns 419 
and splice variants in actinic keratosis and cutaneous squamous cell carcinoma. 420 
Br.J.Dermatol. 2006;155:763-770. 421 
 27.  Chiquet-Ehrismann,R, Chiquet,M. Tenascins: regulation and putative functions during 422 
pathological stress. J.Pathol. 2003;200:488-499. 423 
 28.  Roepman,P, Wessels,LF, Kettelarij,N et al. An expression profile for diagnosis of lymph 424 
node metastases from primary head and neck squamous cell carcinomas. Nat.Genet. 425 
2005;37:182-186. 426 
 29.  Schmalbach,CE, Chepeha,DB, Giordano,TJ et al. Molecular profiling and the identification 427 
of genes associated with metastatic oral cavity/pharynx squamous cell carcinoma. 428 
Arch.Otolaryngol.Head Neck Surg. 2004;130:295-302. 429 
 30.  O'donnell,RK, Kupferman,M, Wei,SJ et al. Gene expression signature predicts lymphatic 430 
metastasis in squamous cell carcinoma of the oral cavity. Oncogene. 2005;24:1244-1251. 431 
 31.  Marcus,B, Arenberg,D, Lee,J et al. Prognostic factors in oral cavity and oropharyngeal 432 
squamous cell carcinoma. Cancer. 2004;101:2779-2787. 433 
 32.  Reichert,TE, Scheuer,C, Day,R, Wagner,W, Whiteside,TL. The number of intratumoral 434 
dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in 435 
patients with oral carcinoma. Cancer. 2001;91:2136-2147. 436 
 33.  Badoual,C, Hans,S, Rodriguez,J et al. Prognostic value of tumor-infiltrating CD4+ T-cell 437 
subpopulations in head and neck cancers. Clin Cancer Res. 2006;12:465-472. 438 
 34.  Pawelec,G. Tumour escape: antitumour effectors too much of a good thing?. [Review] [172 439 
refs]. Cancer Immunol.Immunother. 2004;53:262-274. 440 
 35.  Jeon,GA, Lee,JS, Patel,V et al. Global gene expression profiles of human head and neck 441 
squamous carcinoma cell lines. Int.J.Cancer. 2004;112:249-258. 442 
 36.  Moriya,T, Seki,N, Shimada,K et al. In-house cDNA microarray analysis of gene expression 443 
profiles involved in SCC cell lines. Int. J. of Mol. Med. 2003;12:429-435. 444 
TMA paper  Choi P, et al. 
 
19
 37.  Irie,T, Aida,T, Tachikawa,T. Gene expression profiling of oral squamous cell carcinoma 445 
using laser microdissection and cDNA microarray. Med. Electron Microscopy. 2004;37:89-446 
96. 447 
 38.  Leethanakul,C, Patel,V, Gillespie,J et al. Distinct pattern of expression of differentiation 448 
and growth-related genes in squamous cell carcinomas of the head and neck revealed by 449 
the use of laser capture microdissection and cDNA arrays. Oncogene. 2000;3220-3224. 450 
 39.  Leethanakul,C, Knezevic,V, Patel,V et al. Gene discovery in oral squamous cell carcinoma 451 
through the Head and Neck Cancer Genome Anatomy Project: confirmation by microarray 452 
analysis. Oral Oncol. 2003;39:248-258. 453 
 40.  Hwang,D, Alevizos,I, Schmitt,WA et al. Genomic dissection for characterization of 454 
cancerous oral epithelium tissues using transcription profiling. Oral Oncol.. 2003;39:259-455 
268. 456 
 41.  Mueller,MM, Fusenig,NE.  Friends or foes – bipolar effects of the tumour stroma in cancer. 457 
Nat Rev Cancer 2004;4:839-849. 458 
 42.  Rosenthal,EL, McCrory,A, Talbert,M, Carroll,W, Magnuson,JS, Peters,GE. Expression of 459 
proteolytic enzymes in head and neck cancer-associated fibroblasts. 460 
Arch.Otolaryngol.Head Neck Surg. 2004;130:943-947. 461 
 43.  Rosenthal,E, McCrory,A, Talbert,M, Young,G, Murphy-Ullrich,J, Gladson,C. Elevated 462 
expression of TGF-beta1 in head and neck cancer-associated fibroblasts. Mol.Carcinog. 463 
2004;40:116-121. 464 
 44.  Ziober,AF, Falls,EM, Ziober,BL. The extracellular matrix in oral squamous cell carcinoma: 465 
friend or foe? Head & Neck. 2006;28:740-749. 466 
 45.  Weber,F, Xu,Y, Zhang,L et al. Microenvironmental genomic alterations and 467 
clinicopathological behavior in head and neck squamous cell carcinoma. JAMA. 468 
2007;297:187-195. 469 
 470 
 471 
 472 
 473 
 474 
 475 
 476 
 477 
TMA paper  Choi P, et al. 
 
20
Figure 1 – IHC of OSCC TMA sections 478 
Representative tissue cores are shown.  (A)  SPARC IHC of normal mucosa – Occasional faint 479 
staining of vessels and fibroblasts was identified.  Virtually no epithelial staining was seen.  (B) 480 
SPARC IHC of a T4N2bM0 primary OSCC – Increased staining was observed, mostly within 481 
vessels and fibroblasts of the stroma, but also within some carcinoma cells.  (C)  Periostin IHC 482 
of normal mucosa – Focal faint-to-moderate vascular staining and very focal faint subepithelial 483 
stromal staining was identified.  (D) Periostin IHC of T4N2bM0 primary OSCC – Strong 484 
staining localized primarily within the ECM and stromal fibroblasts.  Many late stage tumors 485 
also exhibited modest staining within cancer epithelium, as in this case.  (E)  Tenascin-C IHC of 486 
normal mucosa – A narrow zone of faint-to-moderate stromal staining was identified beneath the 487 
basal layer of normal epithelium.  (F)  Tenascin-C IHC of T4N2bM0 primary OSCC – Strong 488 
staining was observed mostly within the carcinoma-associated stroma.   (G) Transglutaminase-3 489 
IHC of normal mucosa – Moderate-to-strong staining was seen in suprabasal epithelium of all 490 
normal mucosa.  (H) Transglutaminase-3 IHC of T4N2bM0 primary OSCC – Although some 491 
OSCC tumors exhibited faint epithelial staining, primarily in more differentiated and keratinized 492 
regions, many tumors did not stain at all, as in this case. 493 
 494 
 495 
 496 
 497 
 498 
 499 
 500 
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 501 
Table 1 – Characteristics of Specimens Used in qRT-PCR Analyses 502 
 503 
Specimen Age Sex Diagnosis Stage Grade 
Normal 43 M Obstructive sleep apnea T0N0M0 N/A 
Normal 37 M Obstructive sleep apnea T0N0M0 N/A 
Normal 48 F Obstructive sleep apnea T0N0M0 N/A 
Normal 48 M Buccal mucosa from patient with lateral tongue SCCA T2N0M0 N/A 
Normal 54 F Buccal mucosa from patient with lateral tongue SCCA T2N0M0 N/A 
Normal 64 M Palate mucosa from patient with tonsil/palate SCCA T2N2bM0 N/A 
Cancer 48 M Lateral tongue SCCA T2N0M0 moderate 
Cancer 81 F Retromolar trigone SCCA T4N2bM0 moderate-to-poor 
Cancer 63 M Tonsil/soft palate SCCA T2N2bM0 moderate 
Cancer 61 M Retromolar trigone SCCA T4N2bM0 moderate 
Cancer 76 M Gingivobuccal sulcus SCCA T4N0M0 moderate 
Cancer 54 F Lateral tongue SCCA T2N0M0 moderate 
SCCA = squamous cell carcinoma 504 
 505 
 506 
 507 
 508 
 509 
 510 
 511 
 512 
 513 
 514 
 515 
 516 
 517 
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Table 2 – Characteristics of Tissue Microarray Specimens  518 
 519 
Case Specimen(s) Age Sex Diagnosis Stage Grade 
1 NLn 43 M Obstructive sleep apnea T0N0M0 N/A 
2 NLn 37 M Obstructive sleep apnea T0N0M0 N/A 
3 NLn 48 F Obstructive sleep apnea T0N0M0 N/A 
4 T, LN 51 F Lateral tongue SCCA T4N2bM0 well-to-moderate 
5 NLc, T 48 M Lateral tongue SCCA T2N0M0 moderate 
6 T, LN 81 F Retromolar trigone SCCA T4N2bM0 moderate-to-poor 
7 NLc, T, LN 46 F Lateral tongue SCCA T2N2bM1 well 
8 NLc, T, LN 63 M Tonsil/soft palate SCCA T2N2bM0 moderate 
9 T, LN 61 M Retromolar trigone SCCA T4N2bM0 moderate 
10 NLc, T 76 M Gingivobuccal sulcus SCCA T4N0M0 moderate 
11 NLc, T, LN 54 M Tonsil/soft palate SCCA T4N2bM0 moderate 
12 NLc, T, LN 77 M Floor of mouth SCCA T1N2bM0 well-to-moderate 
13 NLc, T 54 F Lateral tongue SCCA T2N0M0 moderate 
14 CIS, NLc 28 M Lateral tongue leukoplakia TisN0M0 CIS 
15 CIS 83 F Lower lip leukoplakia TisN0M0 CIS 
16 NLc, T 39 F Recurrent floor of mouth SCCA T2N0M0 well 
17 T 51 M Floor of mouth SCCA T2N0M0 moderate 
18 CIS 49 M Floor of mouth leukoplakia TisN0M0 CIS 
19 NLc, T 50 M Lateral tongue SCCA T2N0M0 moderate 
20 LN 57 M Posterior tongue SCCA T1N2bM0 not available 
21 T, LN 88 F Retromolar trigone SCCA T4N2bM0 well 
22 NLc, T, LN 61 M Base of tongue SCCA T3N2bM0 well-to-moderate 
23 NLc, T 63 M Lateral tongue SCCA T1N2bM0 moderate-to-poor 
24 T, LN 62 M Recurrent lateral tongue SCCA T2N2bM0 poor 
25 NLc, T, LN 52 M Anterior tongue SCCA T3N1M0 well 
26 NLc, T, LN 62 M Lateral tongue SCCA T2N2bM0 moderate 
27 NLc, T, LN 62 M Base of tongue SCCA T3N2bM0 moderate 
28 T, LN 70 M Base of tongue SCCA T3N2bM0 poor 
29 T, LN 76 M Lateral tongue SCCA T4N2bM0 moderate 
30 NLc, T, LN 85 M Lateral tongue SCCA T3N2bM0 moderate 
31 T 81 M Lateral tongue SCCA T4N0M0 well 
NLc = matched normal from cancer/CIS patients, NLn = unmatched normal from normal patients,  520 
T = primary tumor, LN = lymph node metastasis, SCCA = squamous cell carcinoma 521 
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Table 3 - qRT-PCR Validation of Gene Microarray Data 522 
 523 
Gene Method CA:NML Ratio1 Linear Correlation 
CDH11 microarray 19.8 (p=0.003) r = 0.45, p ≤ 0.14 
  qRT-PCR 18.9 (p=0.03)  
     
MMP3 microarray 22.9 (p=0.09) r = 0.97, p ≤ 0.0004  
 qRT-PCR 4.30 (p=0.10)  
    
SPARC microarray 5.67 (p=0.001) r = 0.91, p ≤ 0.0002 
 qRT-PCR 3.90 (p=0.001)  
    
POSTN microarray 18.8 (p=0.008) r = 0.90, p ≤ 0.0003 
 qRT-PCR 4.52 (p=0.009)  
    
TNC microarray 7.80 (p=0.0003) r = 0.90, p ≤ 0.0003 
  qRT-PCR 6.67 (p<0.0001)  
 
TGM3 microarray 0.057 (p<0.0001) r = 0.63, p ≤ 0.03 
  qRT-PCR 0.068 (p=0.03)  
1CA:NML = cancer-to-normal 524 
 525 
 526 
 527 
 528 
 529 
 530 
 531 
 532 
 533 
 534 
 535 
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Table 4 – Analysis of IHC Scores for SPARC, Periostin, Tenascin-C, and 537 
Transglutaminase-3 538 
 539 
 540 
Columns A-D list IHC scores for the specified tissues.  P-values for unpaired student t-tests are 541 
listed in the remaining columns.   542 
CIS = carcinoma in-situ, ECM = extracellular matrix, LN = lymph node, TGM3 = 543 
transglutaminase-3, TNC = tenascin-C 544 
 A 
Primary 
Tumor 
B 
 
Normal
C 
 LN 
Tumor
D 
 
CIS 
A vs B 
P-value 
A vs C 
P-value 
A vs D 
P-value 
B vs D 
P-value 
TNCepithelium 1.45 0.07 1.13 1.00 .0009 .5720 .5215 .5215 
TNCECM 5.09 2.61 4.01 4.00 .0084 .3590 .0333 .0333 
Periostinepithelium 1.28 0.45 0.38 0.83 .1057 .0181 .6214 .6214 
PeriostinECM 5.76 3.38 3.34 4.00 .0017 .0037 .8087 .8087 
Periostinfibroblast 5.48 3.31 3.84 3.25 .0034 .0373 .9714 .9714 
SPARCepithelium 1.90 0.27 1.39 1.67 .0002 .4673 .3005 .3005 
SPARCfibroblast 8.56 4.69 6.63 7.00 .0000 .0268 .0312 .0312 
SPARCvessels 6.96 4.12 6.70 8.25 .0000 .7081 .0532 .0532 
TGM3epithelium 0.31 5.44 0.44 0.92 .0000 .6665 .0000 .0000 

